RadNet (RadNet) GF Value : $27.71 (As of Apr. 27, 2024)

View and export this data going back to 1997. Start your Free Trial

What is RadNet GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-27), RadNet's share price is $48.40. RadNet's GF Value is $27.71. Therefore, RadNet's Price-to-GF-Value for today is 1.75.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes RadNet is Significantly Overvalued.

RadNet (NAS:RDNT) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

RadNet's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	48.40	/	27.71
	=	1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RadNet GF Value Related Terms

Thank you for viewing the detailed overview of RadNet's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

RadNet (RadNet) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RadNet Inc (NAS:RDNT) » Definitions » GF Value

Comparable Companies

NEOG SHC GH NEO TWST MYGN VCYT OPK LAB FLGT TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

PQIA:Germany

Address

1510 Cotner Avenue, Los Angeles, CA, USA, 90025

Website

http://www.radnet.com

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

Executives

Michael N Murdock	officer: Executive Vice President	3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 752012776
Christine Nayoma Gordon	director	3081 PANAMA AVE., CARMICHAEL CA 95608
Gregory Sorensen	director, officer: EVP Chief Science Officer	C/O DFB HEALTHCARE ACQUISITIONS CORP, 780 THIRD AVENUE, NEW YORK NY 10017
Norman R Hames	director, officer: Vice President
Stephen M Forthuber	officer: Executive Vice President	3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 75201-2776
Ruth Louisa Villigerwilson	director, officer: Senior Vice President	3700 WALNUT AVENUE, LONG BEACH CA 90801
David L Swartz	director	1510 COTNER AVENUE, LOS ANGELES CA 90025
Gregory E. Spurlock	director	4116 E. NORTHRIDGE CIRCLE, MESA AZ 85215-9807
John V Crues	director	1510 COTNER AVE, LOS ANGELES CA 90025
Lawrence L Levitt	director	2934 1/2 BEVERLY GLEN CIRCLE #325, LOS ANGELES CA 90077
Ranjan Jayanathan	officer: Chief Information Officer	13388 HUNT RIDGE ROAD, ELLICOTT CITY MD 21042
Laura Pastre Jacobs	director	10154 BRIDLEVALE DRIVE, LOS ANGELES CA 90064
Karen B. Kaplan Survivor's Trust	other: Indirect owner	10776 WILSHIRE BLVD/, LOS ANGELES CA 90024-6447
David Jeffrey Katz	officer: EVP and General Counsel	1510 COTNER AVE, LOS ANGELES CA 90025
Sherman Michael L Md	director